Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 432
Filtrar
1.
Pediatr Blood Cancer ; 71(12): e31330, 2024 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-39267234

RESUMEN

Pancreaticoduodenectomy with vascular reconstruction is rarely performed in children. We present a 3-year-old male with stage IV hepatoblastoma and pre-treatment extent of disease (PRETEXT) stage III with tumor into the portal vein and superior mesenteric vein (SMV), and with brain and lung metastases status post chemotherapy and stereotactic radiosurgery to left frontal brain lesion. He then underwent deceased donor liver transplant with Roux-en-Y hepaticojejunostomy complicated by two recurrences to bilateral lungs treated with wedge resections. His course lastly involved a third hepatoblastoma recurrence to the SMV that was managed with pylorus-preserving pancreaticoduodenectomy with SMV resection and reconstruction.


Asunto(s)
Hepatoblastoma , Neoplasias Hepáticas , Trasplante de Hígado , Venas Mesentéricas , Recurrencia Local de Neoplasia , Pancreaticoduodenectomía , Humanos , Masculino , Pancreaticoduodenectomía/métodos , Hepatoblastoma/cirugía , Hepatoblastoma/patología , Trasplante de Hígado/métodos , Preescolar , Neoplasias Hepáticas/cirugía , Neoplasias Hepáticas/patología , Venas Mesentéricas/cirugía , Venas Mesentéricas/patología , Recurrencia Local de Neoplasia/cirugía , Recurrencia Local de Neoplasia/patología , Procedimientos de Cirugía Plástica/métodos , Píloro/cirugía , Píloro/patología
2.
Pediatr Blood Cancer ; 71(12): e31339, 2024 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-39334537

RESUMEN

BACKGROUND: There is ongoing debate regarding liver transplantation (LT) versus liver resection (LR) for locally advanced hepatoblastoma. However, comparative studies are lacking. Consequently, a significant evidence gap persists, hindering the establishment of consensus guidelines. This study aimed to compare LT and LR for locally advanced hepatoblastoma, using predefined inclusion criteria to ensure comparable intervention groups. METHODS: According to current Children's Oncology Group (COG) and SIOPEL (European Childhood Liver Tumour Study Group) recommendations, hepatoblastoma that requires LT evaluation was defined as either PRETEXT (PRE-Treatment EXTent of tumor) IV F+, POST-TEXT (POST-Treatment EXTent of tumor) IV, POST-TEXT P+, and/or POST-TEXT V+. A systematic literature search (Medline/Web-of-Science/Embase) was performed. Only patients who met the aforementioned criteria were included. Patient data were extracted individually and pooled. RESULTS: A total of 189 patients with locally advanced hepatoblastoma from 55 studies met the specified criteria, with 111 undergoing LT and 78 LR. There were no significant differences between the two groups in age, alpha-fetoprotein (AFP), and PRETEXT stages. Local recurrence was more common after LR (14% vs. 3% in LT, p = .008), while distant recurrence was more often observed after LT (16% vs. 5% in LR, p = .035). Overall survival (OS) and event-free survival (EFS) did not differ significantly between LT and LR (5-year OS: LT = 75.3% [95% confidence interval: 66.5-85.2], LR = 87.6% [80.4-95.6], p = .140; 5-year EFS: LT = 68.5% [59.3-79.1], LR = 71.1% [60.7-83.3], p = .700). CONCLUSION: Real-life data revealed that a considerable number of patients with locally advanced hepatoblastoma underwent LR. This analysis suggests that outcomes are similar and favorable for both approaches. LR can therefore be considered an effective alternative to LT in selected cases even in locally advanced hepatoblastoma.


Asunto(s)
Hepatectomía , Hepatoblastoma , Neoplasias Hepáticas , Trasplante de Hígado , Humanos , Hepatoblastoma/cirugía , Hepatoblastoma/patología , Hepatoblastoma/mortalidad , Neoplasias Hepáticas/cirugía , Neoplasias Hepáticas/patología , Neoplasias Hepáticas/mortalidad , Trasplante de Hígado/mortalidad , Hepatectomía/mortalidad , Hepatectomía/métodos , Tasa de Supervivencia , Pronóstico , Niño , Recurrencia Local de Neoplasia/patología , Recurrencia Local de Neoplasia/cirugía
3.
Pediatr Surg Int ; 40(1): 223, 2024 Aug 14.
Artículo en Inglés | MEDLINE | ID: mdl-39141149

RESUMEN

PURPOSE: Recently, children with trisomy 18 have been receiving more active treatment for malignancies. We report herein seven cases complete resection was achieved, and discuss multidisciplinary treatment for hepatoblastoma in patients with trisomy 18. METHOD: The medical records of children with trisomy 18 who were treated at the study center between 2010 and 2023 were reviewed. RESULT: Six of 69 patients had hepatoblastoma development, and three of these underwent multidisciplinary treatment. In addition, 6 patients had been referred by another hospital for treatment, and four of these underwent multidisciplinary treatment. Among the seven patients who underwent multidisciplinary treatment, three, two, and two were categorized in Pre-treatment Extent of Disease (PRETEXT) classification group I, II, and III, respectively. Neoadjuvant chemotherapy resulting in tumor reduction was performed in three cases. In all the cases, complete resection was achieved with pathologically safe margins. Perioperative complications included circulatory failure in one case and bile leakage in two cases. Adjuvant chemotherapy was administered in four cases. The postoperative observation period ranged from 3 months to 11 years, and all the patients are recurrence-free. CONCLUSION: Children with trisomy 18 complicated with hepatoblastoma whose cardiopulmonary conditions are stable may be good candidates for chemotherapy and surgery.


Asunto(s)
Hepatoblastoma , Neoplasias Hepáticas , Síndrome de la Trisomía 18 , Humanos , Hepatoblastoma/genética , Hepatoblastoma/cirugía , Síndrome de la Trisomía 18/complicaciones , Síndrome de la Trisomía 18/genética , Síndrome de la Trisomía 18/cirugía , Masculino , Neoplasias Hepáticas/cirugía , Neoplasias Hepáticas/genética , Femenino , Lactante , Preescolar , Estudios Retrospectivos , Hepatectomía/métodos , Niño , Resultado del Tratamiento , Trisomía/genética
4.
Pediatr Surg Int ; 40(1): 230, 2024 Aug 17.
Artículo en Inglés | MEDLINE | ID: mdl-39154089

RESUMEN

BACKGROUND: Surgical resection remains the cornerstone of treatment for hepatoblastoma in children and offers the best chance of disease-free survival. We aimed to analyze the 30 day outcomes of hepatic resection for hepatoblastoma stratified by extent using the National Surgical Quality Improvement Program-Pediatric (NSQIP-P). METHODS: We queried NSQIP-P for children undergoing resection of Hepatoblastoma from 2012 to 2021. Relevant clinical characteristics and outcomes were extracted for multivariate logistic regression to identify predictors of common adverse outcomes. RESULTS: We included 458 children with a median age of 1.90 years. Overall complications were rare, and perioperative blood transfusion (64.2%) and postoperative ventilation > 48 h (10.0%) were the only adverse events prevalent in more than 5% of patients. Median transfusion volume was 15.7 ml/kg. On multivariate regression, only patients undergoing Trisectionectomy (aOR = 3.387, 95% C.I. = 1.348-8.510) had higher odds of receiving > 75th percentile blood transfusion. Furthermore, only perioperative transfusion and postoperative ventilation > 48 h were statistically more common in patients undergoing extended versus standard resections. CONCLUSIONS: Outcomes following resection of hepatoblastoma are excellent, with low rates of postoperative adverse events. Although children undergoing trisectionectomy likely require greater transfusion volume, extended hepatic resections do not appear to have worse 30 day outcomes despite greater operative complexity and duration.


Asunto(s)
Bases de Datos Factuales , Hepatectomía , Hepatoblastoma , Neoplasias Hepáticas , Complicaciones Posoperatorias , Mejoramiento de la Calidad , Humanos , Hepatoblastoma/cirugía , Neoplasias Hepáticas/cirugía , Femenino , Lactante , Hepatectomía/métodos , Masculino , Preescolar , Niño , Complicaciones Posoperatorias/epidemiología , Resultado del Tratamiento , Estudios Retrospectivos , Transfusión Sanguínea/estadística & datos numéricos , Estados Unidos
5.
Asian J Surg ; 47(5): 2132-2137, 2024 May.
Artículo en Inglés | MEDLINE | ID: mdl-38331610

RESUMEN

Hepatoblastoma (HB) is the most common liver malignancy in children, accounting for approximately 60 % of liver tumors in this population. However, the exact cause of HB remains unclear. The combination of surgery and neoadjuvant chemotherapy has significantly improved the overall survival rate of children with HB, increasing it from 40 % in the past to over 70 %. The concept of precise hepatectomy, which aims to achieve the best rehabilitation outcomes with minimal trauma and maximum liver protection, has been widely accepted by hepatobiliary surgeons. This article provides a comprehensive review of the recent advancements in surgical treatment of HB, focusing on digital surgery and minimally invasive techniques.


Asunto(s)
Hepatectomía , Hepatoblastoma , Neoplasias Hepáticas , Procedimientos Quirúrgicos Mínimamente Invasivos , Humanos , Hepatoblastoma/cirugía , Neoplasias Hepáticas/cirugía , Procedimientos Quirúrgicos Mínimamente Invasivos/métodos , Niño , Hepatectomía/métodos , Terapia Neoadyuvante
6.
J Pediatr ; 269: 113963, 2024 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-38369237

RESUMEN

OBJECTIVE: To evaluate for disparities in surgical care among US children with hepatoblastoma (HB) and hepatocellular carcinoma (HCC). STUDY DESIGN: In this retrospective National Cancer Database study (2004-2015), children aged <18 years with HB or HCC were included. Multivariable mixed-effects logistic regression was used to evaluate the association of sociodemographic factors (age, sex, race and ethnicity, insurance status, income, proximity to treating hospital) with the odds of undergoing surgical treatment after adjusting for disease-related factors (tumor size, metastasis, comorbidities) and hospital-level effects. Subgroup analyses by tumor histology were performed. RESULTS: A total of 811 children were included (HB: 80.9%; HCC: 19.1%), of which 610 (75.2%) underwent surgical treatment. Following adjustment, decreased odds of undergoing surgical treatment were associated with Black race (OR: 0.46 vs White, 95% CI [95% CI]: 0.26-0.80, P = .01), and having Medicaid (OR: 0.58 vs private, 95% CI: 0.38-0.88, P = .01) or no insurance (OR: 0.33 vs private, 95% CI: 0.13-0.80, P = .02). In children with HB, Black race was associated with decreased odds of undergoing surgical treatment (OR: 0.47 vs White, 95% CI: 0.25-0.89, P = .02). In children with HCC, Medicaid (OR: 0.10 vs private, 95% CI: 0.03-0.35, P < .001), or no insurance status (OR: 0.10 vs private, 95% CI: 0.01-0.83, P = .03) were associated with decreased odds of undergoing surgical treatment. Other than metastatic disease, no additional factors were associated with likelihood of surgical treatment in any group. CONCLUSIONS: Black race and having Medicaid or no insurance are independently associated with decreased odds of surgical treatment in children with HB and HCC, respectively. These children may be less likely to undergo curative surgery for their liver cancer.


Asunto(s)
Carcinoma Hepatocelular , Disparidades en Atención de Salud , Hepatoblastoma , Neoplasias Hepáticas , Humanos , Hepatoblastoma/cirugía , Carcinoma Hepatocelular/cirugía , Neoplasias Hepáticas/cirugía , Neoplasias Hepáticas/patología , Masculino , Femenino , Niño , Estudios Retrospectivos , Preescolar , Lactante , Estados Unidos , Disparidades en Atención de Salud/estadística & datos numéricos , Disparidades en Atención de Salud/etnología , Adolescente , Factores Sociodemográficos , Medicaid/estadística & datos numéricos , Factores Socioeconómicos , Bases de Datos Factuales
7.
Pediatr Res ; 96(3): 668-677, 2024 Aug.
Artículo en Inglés | MEDLINE | ID: mdl-38263451

RESUMEN

BACKGROUND: Twenty percent of children with hepatoblastoma (HB) have lung metastasis at diagnosis. Treatment protocols recommend surgical removal of chemotherapy-refractory lung nodules, however no chronological order is established. As hepatectomy is followed by release of growth factors, it has been proposed that partial hepatectomy (PH) could boost local or distant residual tumor growth. METHODS: To evaluate the impact of PH on distant tumor growth, PH was performed in mice subcutaneously implanted with a HB patient-derived xenograft (PDX). The influence of PH on tumor growth at primary site was assessed by performing PH concomitantly to HB PDXs orthotopic implantation. RESULTS: Subcutaneously implanted HB PDX failed to show any influence of hepatectomy on tumor growth. Instead, intrahepatic tumor growth of one of the 4 HB PDXs implanted orthotopically was clearly enhanced. Cells derived from the hepatectomy-sensitive HB PDX exposed to hepatic growth factor (HGF) showed increased proliferation rate compared to cells derived from a hepatectomy-insensitive model, suggesting that the HGF/MET pathway could be one of the effectors of the crosstalk between liver regeneration and HB growth. CONCLUSION: These results suggest that hepatectomy can contribute to HB growth in some patients, further studies will be necessary to identify biomarkers predictive of patient risk of PH-induced HB recurrence. IMPACT: Key message: Cytokines and growth factors secreted following partial hepatectomy can contribute to intrahepatic tumor growth in some hepatoblastoma models. What does it add to the existing literature: It is the first article about the impact of liver regeneration induced by partial hepatectomy on hepatoblastoma local or distant tumoral growth in nude mice. What is the impact: It is important to identify the secreted factors that enhance tumor growth and to define biomarkers predictive of patient risk of partial hepatectomy-induced hepatoblastoma recurrence.


Asunto(s)
Hepatectomía , Hepatoblastoma , Factor de Crecimiento de Hepatocito , Neoplasias Hepáticas , Regeneración Hepática , Hepatoblastoma/cirugía , Hepatoblastoma/patología , Hepatoblastoma/metabolismo , Animales , Humanos , Neoplasias Hepáticas/cirugía , Neoplasias Hepáticas/patología , Ratones , Factor de Crecimiento de Hepatocito/metabolismo , Proliferación Celular , Xenoinjertos , Modelos Animales de Enfermedad
8.
Cardiol Young ; 34(4): 927-929, 2024 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-38247377

RESUMEN

Primary liver tumours in neonates with single-ventricle palliation are exceedingly rare. We present the first reported case of neonatal hepatoblastoma with severe Ebstein's anomaly following Starnes procedure. The patient's postoperative course highlights the challenges and complications in simultaneous management of these diagnoses. Transition from shunted single-ventricle physiology to bidirectional cavopulmonary connection improved end-organ function, permitting more aggressive hepatic malignancy treatment.


Asunto(s)
Anomalía de Ebstein , Hepatoblastoma , Neoplasias Hepáticas , Corazón Univentricular , Recién Nacido , Humanos , Anomalía de Ebstein/diagnóstico , Anomalía de Ebstein/cirugía , Anomalía de Ebstein/complicaciones , Hepatoblastoma/diagnóstico , Hepatoblastoma/cirugía , Hepatoblastoma/complicaciones , Corazón Univentricular/complicaciones , Neoplasias Hepáticas/diagnóstico , Neoplasias Hepáticas/cirugía , Neoplasias Hepáticas/complicaciones
9.
Cancer Med ; 13(1): e6795, 2024 Jan.
Artículo en Inglés | MEDLINE | ID: mdl-38180290

RESUMEN

Hepatoblastoma, a common extracranial malignant solid tumor in childhood, is often detected at an advanced stage and is difficult to treat surgically. Despite the availability of multiple comprehensive treatments that can be combined with surgery, hepatoblastoma treatment outcomes remain poor. Surgery is the main treatment strategy for hepatoblastoma, but it faces many challenges, including tumor attachment to surrounding tissues, tumor wrapping or invading of vital organs and tissues, the presence of giant or multiple tumors, distant metastasis, the formation of a tumor thrombus, and significant surgical trauma. In this review, we discuss recent research advances and propose potential strategies for overcoming these challenges. Such strategies may improve the rate of hepatoblastoma resection and local control in children, as well as reduce complications and trauma.


Asunto(s)
Hepatoblastoma , Neoplasias Hepáticas , Hepatoblastoma/cirugía , Hepatoblastoma/patología , Humanos , Neoplasias Hepáticas/cirugía , Neoplasias Hepáticas/patología , Hepatectomía/métodos , Hepatectomía/tendencias , Resultado del Tratamiento , Niño
10.
J Magn Reson Imaging ; 59(3): 1034-1042, 2024 Mar.
Artículo en Inglés | MEDLINE | ID: mdl-37272790

RESUMEN

BACKGROUND: The assessment of resectability after neoadjuvant chemotherapy of hepatoblastoma is dependent on Post-Treatment EXTENT of Disease (POSTTEXT) staging and its annotation factors P (portal venous involvement) and V (hepatic venous/inferior vena cava [IVC] involvement), but MR performance in assessing them remains unclear. PURPOSE: To assess the diagnostic performance of contrast-enhanced MR imaging for preoperative POSTTEXT staging and diagnosing vascular involvement in terms of annotation factors P and V in pediatric hepatoblastoma following neoadjuvant chemotherapy. STUDY TYPE: Retrospective. SUBJECTS: Thirty-five consecutive patients (17 males, median age, 24 months; age range, 6-98 months) with proven hepatoblastoma underwent preoperative MR imaging following neoadjuvant chemotherapy. FIELD STRENGTH/SEQUENCE: 3.0 T; T2-weighted imaging (T2WI), T2WI with fat suppression, diffusion weighted imaging, radial stack-of-the-star/Cartesian 3D Dixon T1-weighted gradient echo imaging. ASSESSMENT: Three radiologists independently assessed the POSTTEXT stages and annotation factors P and V based on the 2017 PRE/POSTTEXT system. The sensitivities and specificities were calculated for 1) diagnosing each POSTTEXT stage; 2) discrimination of stages III and IV (advanced) from those stages I and II (non-advanced) hepatoblastomas; and 3) annotation factors P and V. The combination of pathologic findings and surgical records served as the reference standard. STATISTICAL TESTS: Sensitivity, specificity, Fleiss kappa test. RESULTS: The sensitivity and specificity ranges for discriminating advanced from non-advanced hepatoblastomas were 73.3%-80.0% and 80.0%-90.0%, respectively. For annotation factor P, they were 66.7%-100.0% and 90.6%, respectively. For factor V, they were 75.0% and 67.7%-83.9%, respectively. There was excellent, substantial, and moderate agreement on POSTTEXT staging (Fleiss kappa = 0.82), factors P (Fleiss kappa = 0.64), and factors V (Fleiss kappa = 0.60), respectively. DATA CONCLUSION: MR POSTTEXT provides reliable discrimination between advanced and non-advanced tumors, and MR has moderate to excellent specificity at identifying portal venous and hepatic venous/IVC involvement. EVIDENCE LEVEL: 3 TECHNICAL EFFICACY: Stage 3.


Asunto(s)
Hepatoblastoma , Neoplasias Hepáticas , Masculino , Niño , Humanos , Preescolar , Lactante , Hepatoblastoma/tratamiento farmacológico , Hepatoblastoma/patología , Hepatoblastoma/cirugía , Terapia Neoadyuvante , Estudios Retrospectivos , Imagen por Resonancia Magnética/métodos , Venas Hepáticas , Sensibilidad y Especificidad , Neoplasias Hepáticas/patología , Estadificación de Neoplasias
11.
Pediatr Transplant ; 28(1): e14641, 2024 Feb.
Artículo en Inglés | MEDLINE | ID: mdl-37946593

RESUMEN

BACKGROUND: Liver transplantation (LT) is the only potentially curative option for children with unresectable hepatoblastoma (HBL). Although post-transplant outcomes have improved in the contemporary era, the impact of donor graft type on survival remains unclear. METHODS: Using the United Network for Organ Sharing database (02/2002-06/2021), demographics, clinical characteristics, and patient and graft survival were analyzed in children (<18 years) who underwent LT for HBL according to donor graft type. The Kaplan-Meier method, log-rank tests, and Cox regression modeling were used to evaluate the effect of whole, partial, and split deceased donor liver transplantation (DDLT) and living donor liver transplantation (LDLT) on patient and graft survival. RESULTS: A total of 590 pediatric HBL LT recipients (344 whole graft DDLT; 62 partial graft DDLT; 139 split graft DDLT; 45 LDLT) were included. During 2012-2021 the proportion of LDLTs for HBL decreased to about 5% compared with about 11% during 2002-2011. No significant differences were identified by donor graft type in either patient survival (log-rank test, p = .45) or graft survival (log-rank test, p = .69). The results remained similar during the 2002-2011 era, while during the 2012-2021 era, split graft DDLT was associated with decreased graft loss risk versus whole graft DDLT (hazard ratio: 0.48, 95% confidence interval: 0.23-0.99, p = .046) without any other significant between-group differences. CONCLUSIONS: Utilizing non-whole liver grafts can increase access to LT in children with unresectable HBL while ensuring favorable outcomes. LDLT is underutilized in children with HBL in the United States, and efforts to explore LDLT options should be undertaken.


Asunto(s)
Hepatoblastoma , Neoplasias Hepáticas , Trasplante de Hígado , Niño , Humanos , Estados Unidos , Donadores Vivos , Trasplante de Hígado/métodos , Hepatoblastoma/cirugía , Estudios Retrospectivos , Supervivencia de Injerto , Neoplasias Hepáticas/cirugía , Resultado del Tratamiento
12.
Pediatr Transplant ; 28(1): e14645, 2024 Feb.
Artículo en Inglés | MEDLINE | ID: mdl-38013236

RESUMEN

BACKGROUND: Hepatic undifferentiated embryonal sarcoma (HUES) is the third most common primary hepatic malignancy in children. If unresectable, liver transplantation (LT) is the only curative option. Historically, HUES LT outcomes were not favorable; however, modern-era data are lacking. We aimed to describe LT outcomes in children with HUES and compared with LT outcomes in children transplanted for hepatoblastoma (HBL) and non-malignancy indications. METHODS: Children 18 years or younger with HUES who underwent LT from 1987 to 2021 were identified from the Scientific Registry of Transplant Recipients database. Graft and patient survival were studied in HUES and LT recipients with HBL and non-malignancy indications using Kaplan-Meier analysis. Cox regression was used to compare patient and graft survival among groups, controlling for confounders. RESULTS: Twenty-one children with HUES underwent LT during the study period with a median age at LT of 10 years (IQR: 8-12 years). One and five-year patient survival for HUES recipients was not significantly different from that of recipients with HBL (p = .3) or non-malignancy diagnoses (p = .6). There were no deaths due to HUES recurrence. In multivariable Cox regression, HUES did not increase risk of either patient or graft loss as compared to HBL (HR 2.36, p = .2) or non-malignancy indications (HR 0.74, p = .7). CONCLUSION: LT outcomes are more favorable in patients with HUES than historically described, and similar to LT outcomes of patients with HBL and non-malignancy indications. Transplant should be considered for HUES patients with unresectable localized tumors.


Asunto(s)
Hepatoblastoma , Neoplasias Hepáticas , Trasplante de Hígado , Sarcoma , Niño , Humanos , Resultado del Tratamiento , Estudios Retrospectivos , Neoplasias Hepáticas/cirugía , Hepatoblastoma/cirugía , Sarcoma/cirugía , Supervivencia de Injerto
14.
Cancer Med ; 12(23): 21270-21278, 2023 12.
Artículo en Inglés | MEDLINE | ID: mdl-37962078

RESUMEN

OBJECTIVE: Hepatoblastoma (HB) is the most common primary hepatic malignancy in childhood. Relapse occurs in more than 50% of high-risk patients with a high mortality due to ineffective salvage therapies. The purpose of this study is to identify risk factors for relapsed HB and predictors of survival in a single tertiary referral center. METHODS: A retrospective chart review showed 129 surgically treated HB patients from October 2004 to July 2020. Of the cohort, 22 patients presented with relapsed HB. Relapse was defined as re-appearance of malignancy after 4 weeks of normalized AFP and disappearance of all tumors on imaging. RESULTS: Patients with relapsed HB had a 5-year overall survival (OS) of 45.4% compared to 93.1% in those without relapse (p = 0.001). When comparing PRETEXT IV, microvascular invasion, metastatic disease, and age on multivariate logistic regression, only PRETEXT IV was an independent risk factor for relapsed HB with an OR of 2.39 (95% CI: 1.16-4.96; p = 0.019). Mixed epithelial and mesenchymal HB (12/19, 63.2%) was the most common histology of primary tumors while pure epithelial HB (13/15, 86.6%) was the most common relapsed histology. Combination of surgical and medical therapy for relapsed disease was predictive of survival with an HR of 16.3 (95% CI: 1.783-149.091; p = 0.013) compared to only chemotherapy. CONCLUSIONS: This study demonstrates that PRETEXT IV staging is an independent predictor of relapsed disease. The most common relapsed histology was epithelial, suggesting a potential selection or resistance of this component. Surgical resection is a critical component of multimodal therapy for relapsed HB.


Asunto(s)
Hepatoblastoma , Neoplasias Hepáticas , Humanos , Lactante , Hepatoblastoma/cirugía , Hepatoblastoma/patología , Estudios Retrospectivos , Pronóstico , Neoplasias Hepáticas/patología , Recurrencia , Resultado del Tratamiento
15.
Semin Pediatr Surg ; 32(5): 151340, 2023 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-38008042

RESUMEN

The appropriate management of pediatric liver malignancies, primarily hepatoblastoma and hepatocellular carcinoma, requires an in depth understanding of contemporary preoperative risk stratification, experience with advanced hepatobiliary surgery, and a good relationship with one's local or regional liver transplant center. While chemotherapy regimens have become more effective, operative indications more well-defined, and overall survival improved, the complexity of liver surgery in small children provides ample opportunity for protocol violation, inadequate resection, and iatrogenic morbidity. These guidelines represent the distillation of contemporary literature and expert opinion as a means to provide a framework for preoperative planning and intraoperative decision-making for the pediatric surgeon.


Asunto(s)
Carcinoma Hepatocelular , Hepatoblastoma , Neoplasias Hepáticas , Trasplante de Hígado , Niño , Humanos , Neoplasias Hepáticas/cirugía , Neoplasias Hepáticas/patología , Hepatoblastoma/cirugía , Hepatoblastoma/patología , Trasplante de Hígado/métodos , Resultado del Tratamiento
16.
Photodiagnosis Photodyn Ther ; 44: 103790, 2023 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-37696318

RESUMEN

BACKGROUND: Indocyanine green (ICG) fluorescence guided surgery has been used to treat childhood hepatoblastoma (HB), but the advantages and disadvantages of this technique have not been fully discussed. The purpose of this study is to summarize the experience and to explore the clinical value of this technique for children with HB. METHODS: 45 children with HB who underwent ICG fluorescence guided surgery (n = 22) and general surgery (n = 23) in our center from January 2020 to December 2022 were enrolled retrospectively. RESULTS: All the liver tumors in the ICG group showed hyperfluorescence, including total and partial fluorescent types. With the help of ICG navigation, minimally invasive surgery was performed in 3 cases. 18.2 % of cases with tumors could not be accurately identified under white light, but could be identified by fluorescence imaging. The fluorescent cutting lines of 59.1 % of cases were consistent with the safe cutting lines. In 36.4 % of cases, the fluorescence boundary was not clear because of tumor necrosis. In 36.4 % of cases, the fluorescence could not be detected on the inner edge of the tumors because of the depth. A total of 29 ICG (+) suspicious lesions were found during the operations, of which 5 were true positive lesions. CONCLUSION: ICG fluorescence guided surgery is safe and feasible in children with HB. This technique is helpful for locating tumors, determining margin and finding small lesions with negative imaging, especially in minimally invasive surgery. However, preoperative chemotherapy, tumor necrosis, tumor depth, and ICG administration impact the effect of fluorescence imaging.


Asunto(s)
Hepatoblastoma , Fotoquimioterapia , Niño , Humanos , Hepatoblastoma/diagnóstico por imagen , Hepatoblastoma/cirugía , Hepatoblastoma/tratamiento farmacológico , Verde de Indocianina/uso terapéutico , Estudios Retrospectivos , Fotoquimioterapia/métodos , Fármacos Fotosensibilizantes/uso terapéutico , Colorantes , Imagen Óptica/métodos , Resultado del Tratamiento , Necrosis/tratamiento farmacológico
17.
Pediatr Surg Int ; 39(1): 253, 2023 Aug 25.
Artículo en Inglés | MEDLINE | ID: mdl-37624479

RESUMEN

Pediatric liver transplantation is a lifesaving state-of-the-art operation for children with various liver diseases, including cholestatic diseases, metabolic disorders, acute liver failure, and primary malignant liver tumors. Among these indications, transplantation for biliary atresia and hepatoblastoma is discussed in this review because pediatric surgeons are usually involved in their initial treatments. For biliary atresia, pediatric surgeons are advised to keep dissection of the hilar structures to a minimum during Kasai portoenterostomy in order to make total hepatectomy easier at transplantation. Early referral to a transplant team is recommended when worrisome signs of liver dysfunction, cirrhosis, portal hypertension and growth retardation are noted. Hepatoblastoma with multiplicity or located close to major vessels may indicate unresectability, and the transplant team needs to be consulted early after neoadjuvant chemotherapy is started. The graft size, including its thickness, needs to be evaluated before transplantation for small children, as tailoring the shape of the partial graft may be necessary during the transplant procedure.


Asunto(s)
Atresia Biliar , Hepatoblastoma , Neoplasias Hepáticas , Trasplante de Hígado , Cirujanos , Niño , Humanos , Atresia Biliar/cirugía , Hepatoblastoma/cirugía
18.
J Pediatr Surg ; 58(9): 1715-1726, 2023 Sep.
Artículo en Inglés | MEDLINE | ID: mdl-37244849

RESUMEN

OBJECTIVE: To compare the outcomes of patients with multifocal hepatoblastoma (HB) treated at our institution with either orthotopic liver transplant (OLTx) or hepatic resection to determine outcomes and risk factors for recurrence. BACKGROUND: Multifocality in HB has been shown to be a significant prognostic factor for recurrence and worse outcome. The surgical management of this type of disease is complex and primarily involves OLTx to avoid leaving behind microscopic foci of disease in the remnant liver. METHODS: We performed a retrospective chart review on all patients <18 years of age with multifocal HB treated at our institution between 2000 and 2021. Patient demographics, operative procedure, post-operative course, pathological data, laboratory values, short- and long-term outcomes were analyzed. RESULTS: A total of 41 patients were identified as having complete radiologic and pathologic inclusion criteria. Twenty-three (56.1%) underwent OLTx and 18 (43.9%) underwent partial hepatectomy. Median length of follow-up across all patients was 3.1 years (IQR 1.1-6.6 years). Cohorts were similar in rates of PRETEXT designation status identified on standardized imaging re-review (p = .22). Three-year overall survival (OS) estimate was 76.8% (95% CI: 60.0%-87.3%). There was no difference in rates of recurrence or overall survival in patients who underwent either resection or OLTx (p = .54 and p = .92 respectively). Older patients (>72 months), patients with a positive porta hepatis margin, and patients with associated tumor thrombus experienced worse recurrence rates and survival. Histopathology demonstrating pleomorphic features independently associated with worse rates of recurrence. CONCLUSIONS: Through proper patient selection, multifocal HB was adequately treated with either partial hepatectomy or OLTx with comparable outcome results. HB with pleomorphic features, increased patient age at diagnosis, involved porta hepatis margin on pathology, and the presence of associated tumor thrombus may be associated with worse outcomes regardless of the local control surgery offered. LEVEL OF EVIDENCE: III.


Asunto(s)
Hepatoblastoma , Neoplasias Hepáticas , Humanos , Lactante , Hepatoblastoma/cirugía , Hepatoblastoma/patología , Neoplasias Hepáticas/patología , Estudios Retrospectivos , Hepatectomía/métodos , Márgenes de Escisión , Resultado del Tratamiento , Recurrencia Local de Neoplasia/patología
20.
J Pak Med Assoc ; 73(5): 1120-1122, 2023 May.
Artículo en Inglés | MEDLINE | ID: mdl-37218249

RESUMEN

Hepatic malignancies account for 1-4% of all childhood solid tumours and Hepatoblastoma is the most common malignant liver tumour in children. Its extrahepatic origin is rare. Here we present the case of a three-year-old boy who came with a large non-tender mass in the right upper abdomen for six months. Ultrasound abdomen revealed a huge heterogenous mass anterior to the right kidney and inferior to the liver with internal vascularity and calcifications, mimicking a neuroblastoma. Tru-cut needle biopsy showed foetal-type hepatoblastoma. After neoadjuvant chemotherapy, the tumour was explored. It was found to be adherent to the inferior surface of the liver with no capsular breech. Hence differentiating it from exophytic growth of hepatoblastoma. The tumour was completely resected. The postoperative course was uneventful and adjuvant chemotherapy was given. So far only a few cases of extrahepatic hepatoblastoma have been reported.


Asunto(s)
Carcinoma Hepatocelular , Hepatoblastoma , Neoplasias Hepáticas , Masculino , Niño , Humanos , Preescolar , Hepatoblastoma/diagnóstico por imagen , Hepatoblastoma/cirugía , Hepatoblastoma/tratamiento farmacológico , Neoplasias Hepáticas/diagnóstico por imagen , Neoplasias Hepáticas/cirugía , Neoplasias Hepáticas/tratamiento farmacológico , Carcinoma Hepatocelular/tratamiento farmacológico , Quimioterapia Adyuvante
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA
...